Neutral lipid storage disease, also known as Chanarin-Dorfman syndrome, is a congenital autosomal recessive disorder in which triglycerides build up inside the cells of several tissues, including white blood cells, muscle, liver and fibroblasts. The white cell finding is called the Jordans anomaly. It commonly occurs in two subtypes: a myopathic form in which muscle disease predominates, linked to mutations in the ATGL or PNPLA2 gene, and an ichthyotic form, in which scaling skin predominates, linked to the CGI-58 gene. The ichthyosis is typically a non-bullous congenital ichthyosiform erythroderma with white scaling. Affected people are not typically obese. The atlas records the condition as a description of the disorder and its genetics, not as medical advice.
Facts
Classification
ICD-10 ChapterIV: Endocrine, Nutritional and Metabolic Diseases 1 Communicable or Non-communicable Causative Agent
Causative Agent (category) First Described Sources
1. World Health Organization: ICD-10 Version:2019 - E70-E90 Metabolic disorders
World Health OrganizationCategory E75.5Quote, Category E75.5
E75.5 Other lipid storage disorders
View the Source 2. Neutral lipid storage disease (Wikipedia)
Lead
Neutral lipid storage disease (also known as Chanarin-Dorfman syndrome) is a congenital autosomal recessive disorder
Lead: disease category
Neutral lipid storage disease (also known as Chanarin-Dorfman syndrome) is a congenital autosomal recessive disorder characterized by accumulation of triglycerides in the cytoplasm of leukocytes (Jordans' anomaly), muscle, liver, fibroblasts, and other tissues.
Article text
The first case of neutral lipid storage disease was reported by Maurice Dorfman when he treated two sisters with non-bullous ichthyosiform erythroderma in 1974.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.